Bristol-Myers Squibb Company (BMY) : The money flow analysis of Bristol-Myers Squibb Company (BMY) indicates a $32.33 million of outflow was on downticks, whereas, the investors on Friday gobbled up stocks worth $48.36 million on upticks. The ratio between the upticks and downticks was clearly in favor of the bulls at 1.5 and so was the total money flow at $16.02 million. The bulls lapped up $13.01 million worth of block trades on upticks. The money flow was $13.01 million in block trades, underlining the interest of the bulls in the stock even when the stock was declining.However, the price action shows that the bears had an upper hand in the stock of Bristol-Myers Squibb Company (BMY), pushing it down by -0.04% for the day. The stock slid $0.03 and traded at $75.47 during the day. Nonetheless, the stock is -0.7% over the previous weeks close.
Bristol-Myers Squibb Company (BMY) has been rated by 14 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $100 and the lowest price target forecast is $48. The average forecast of all the analysts is $74.29 and the expected standard deviation is $13.63.
Bristol-Myers Squibb Company (NYSE:BMY): stock turned positive on Friday. Though the stock opened at $75.5, the bulls momentum made the stock top out at $75.98 level for the day. The stock recorded a low of $75 and closed the trading day at $75.68, in the green by 0.24%. The total traded volume for the day was 5,276,211. The stock had closed at $75.5 in the previous days trading.
In a related news, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director of Bristol Myers Squibb Co, Andreotti Lamberto had sold 23,200 shares worth of $1,731,880 in a transaction dated July 7, 2016. In this transaction, 23,200 shares were sold at $74.65 per share.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products across the world. The Companys products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. The Company manufactures its products in the United States, Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers, such as doctors, nurse practitioners, physician assistants, pharmacists, technologists, hospitals, Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print, radio, television, and digital advertising and promotion. In addition, the Company holds rights to F001287, which is a preclinical, small-molecule IDO1-inhibitor.